首页 > 市场调查报告书 > 医疗设备

导管

市场调查报告书

商品编码

1289779

全球肿瘤消融市场 - 2023-2030年

Global Tumor Ablation Market - 2023-2030

出版日期: 2023年06月12日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 约2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

市场概况

全球肿瘤消融市场在2022年达到7.974亿美元，预计到2030年将见证有利可图的增长，达到20.792亿美元。在预测期内（2023-2030年），全球肿瘤消融市场预计将呈现13.1%的复合增长率。

肿瘤消融术可以在局部麻醉下进行，与传统的癌症治疗方法如手术、化疗或放疗相比，其副作用一般较少。肿瘤消融术被用于治疗各种类型的癌症，包括肝癌、肺癌、肾癌和骨癌。

消融技术的进步、癌症发病率的增加、对微创手术需求的上升以及对肿瘤消融术比传统癌症治疗方法的好处认识的提高，是预计在预测期内推动肿瘤消融市场的一些因素。

市场动态

越来越多的FDA批准的肿瘤消融系统在预测期内推动了全球肿瘤消融市场的增长

2022年9月，世界领先的医疗技术公司之一史赛克公司宣布，其OptaBlate骨肿瘤消融系统（OptaBlate）获得美国食品和药物管理局的510（k）许可。OptaBlate技术加入史赛克的介入性脊柱（IVS）产品组合，扩大了其在椎体增生和射频消融方面的核心竞争力，完善了其对转移性椎体骨折的治疗方案组合。

此外，在2020年11月，克利夫兰诊所是世界上第一家使用美国食品和药物管理局最近批准的消融技术的医院，这种技术可以摧毁大型肝脏肿瘤。这种微创手术使用一根针连接到一个强大的150瓦的微波发生器。

与肿瘤消融系统相关的挑战在预测期内阻碍了全球肿瘤消融市场的增长。

射频消融（RFA）被推荐用于治疗与转移性脊柱病变相关的局部疼痛，但在开发新的RFA系统并将其用于儿科介入放射学方面仍存在挑战。主要的挑战是确保RFA系统在不同类型和位置的肿瘤中使用时是安全和有效的。

该系统创建的消融区应破坏整个肿瘤，同时避免对周围健康组织的损害。此外，它应该准确地定位到肿瘤位置，这在身体的某些部位，如肝脏或肺部，尤其具有挑战性。因此，上述因素预计将在预测期内阻碍市场的增长。

COVID-19影响分析

COVID-19的大流行对肿瘤消融市场产生了重大影响。在短期内，由于供应链的中断，选择性手术的延迟，以及病人到医疗机构就诊的减少，市场受到了负面影响。这导致了对肿瘤消融手术和设备的需求下降。

此外，正在开发的新型消融技术，如微波和不可逆电穿孔，预计将推动市场的增长。这些较新的技术与传统的射频消融系统相比具有优势，如更大的消融区和提高针对肿瘤的精度。

俄罗斯与乌克兰的冲突分析

俄罗斯和乌克兰的肿瘤消融市场可能会受到这两个国家之间持续的政治紧张局势的影响。在乌克兰，冲突导致医疗系统陷入困境，这可能导致肿瘤消融手术的使用受到限制，并推迟采用较新的消融技术。

相比之下，俄罗斯对其医疗系统和采用较新的医疗技术进行了大量的投资。然而，对俄罗斯实施的经济制裁和贸易限制限制了其获得更新的消融技术和设备，影响了市场的增长。

Market Overview

The Global Tumor Ablation Market reached US$ 797.4 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 2,079.2 million by 2030. The global tumor ablation market is expected to exhibit a CAGR of 13.1% during the forecast period (2023-2030).

Tumor ablation procedure can be performed under local anesthesia and is generally associated with fewer side effects than traditional cancer treatments like surgery, chemotherapy, or radiation therapy. Tumor ablation is used to treat various types of cancer, including liver cancer, lung cancer, kidney cancer, and bone cancer.

Advancements in ablation technologies, increasing prevalence of cancer, rising demand for minimally invasive procedures, and growing awareness about the benefits of tumor ablation over traditional cancer treatments are some of the factors expected to drive the tumor ablation market over the forecast period.

Market Dynamics

The Increasing FDA Approvals of the Tumor Ablation System are Boosting the Global Tumor Ablation Market Growth During the Forecast Period

In September 2022, Stryker, one of the world's leading medical technology companies, announced that its OptaBlate bone tumor ablation system (OptaBlate) received 510(k) clearance from the U.S. Food and Drug Administration. The addition of the OptaBlate technology to Stryker's Interventional Spine (IVS) portfolio expands on its core competencies in vertebral augmentation and radiofrequency ablation and completes its portfolio of treatment options for metastatic vertebral body fractures.

Additionally, in November 2020, Cleveland Clinic was the first hospital in the world to use a recently FDA-approved ablation technology that can destroy large liver tumors. The minimally invasive procedure uses a single needle connected to a powerful 150-watt microwave generator

Challenges Associated with the Tumor Ablation System are Hampering the Growth of the Global Tumor Ablation Market in the Forecast Period.

Radiofrequency ablation (RFA) is recommended for treating localized pain associated with metastatic spinal lesions, but there are still challenges in developing new RFA systems and using them in pediatric interventional radiology. The main challenge is to ensure that the RFA system is safe and effective for use in different types and locations of tumors.

The ablation zone created by the system should destroy the entire tumor while avoiding damage to surrounding healthy tissue. Moreover, it should be targeted accurately to the tumor location, which is particularly challenging in certain areas of the body such as the liver or lung. Hence, the above factors are expected to hamper the market growth over the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a significant impact on the tumor ablation market. In the short term, the market has been negatively affected due to the disruption of supply chains, delays in elective surgeries, and a decrease in patient visits to healthcare facilities. This has resulted in a decline in the demand for tumor ablation procedures and devices.

Furthermore, the ongoing development of novel ablation technologies, such as microwave and irreversible electroporation, is expected to drive growth in the market. These newer technologies offer advantages over traditional radiofrequency ablation systems, such as a larger ablation zone and increased precision in targeting tumors.

Russia-Ukraine Conflict Analysis

The tumor ablation market in Russia and Ukraine may be impacted by the ongoing political tensions between the two countries. In Ukraine, the conflict has resulted in a struggling healthcare system, which may lead to limited access to tumor ablation procedures and delay the adoption of newer ablation technologies.

In contrast, Russia has invested heavily in its healthcare system and the adoption of newer medical technologies. However, the economic sanctions and trade restrictions imposed on Russia have limit its access to newer ablation technologies and devices, affecting the market's growth.

Segment Analysis

The global tumor ablation market is segmented based on technology, application, treatment mode, and region.

The Liver Cancer Segment is Expected to Hold a Dominant Position in the Market Over the Forecast Period.

The liver cancer segment accounted for the highest market stake accounting for approximately 1/3 of the vaccines market in 2022. Tumor ablation offers several advantages for treating liver cancer, including minimally invasive, high success rates, versatility, and preservation of liver function. Furthermore, the high incidence of liver cancer, favorable reimbursement policies, and advances in ablation technologies are the factors expected to hold the largest market share over the forecast period.

For instance, in the United States, reimbursement policies play a significant role in the use of tumor ablation for liver cancer. The Centers for Medicare and Medicaid Services (CMS) have established reimbursement codes for various tumor ablation procedures, including those for liver cancer. This helps to ensure that patients who undergo these procedures can receive reimbursement from their insurance providers.

Geographical Analysis

The Increasing Prevalence of Cancer, Advancements in Technology, the Availability of Reimbursement for Tumor Ablation Procedures, and the Presence of A Well-Established Healthcare Infrastructure Dominate the North American Region.

North America is expected to dominate the tumor ablation market, accounting for around 1/3rd of this market, with the U.S. being the major contributor.

For instance, newer MWA systems such as directional microwave ablation (DMWA) offer more precise control over the ablation zone, reducing the risk of damage to nearby healthy tissue. Similarly, newer RFA systems with multiple electrodes and real-time temperature monitoring have improved the accuracy and efficacy of the procedure. Cryoablation systems with improved freezing probes and real-time imaging have also become more widely available.

Moreover, the integration of imaging technologies such as ultrasound, computed tomography (CT), and magnetic resonance imaging (MRI) with ablation systems has further improved the accuracy and efficacy of tumor ablation procedures. These technological advancements have expanded the clinical applications of tumor ablation, making it a viable treatment option for a wide range of tumor types and locations.

Hence, owing to the above factors, the North American region is expected to hold the largest market share over the forecast period.

Competitive Landscape

The major global players in the market include: Medtronic, PLC., AngioDynamics Inc., Boston Scientific Corporation, Healthtronics, Inc., BVM Medical Limited, COMSOL Inc., Galil Medical, Inc., INTIO Inc., Misonix, Inc., NeuWave Medical, Inc., and SonaCare Medical, LLC among others.

Why Purchase the Report?

To visualize the global tumor ablation market segmentation based on the technology, application, treatment mode, and region and understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of tumor ablation market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as Excel consisting of key products of all the major players.

The global tumor ablation market report would provide approximately 61 tables, 60 figures, and 195 pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology
3.2. Snippet by Application
3.3. Snippet by Treatment Mode
3.4. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. The increasing FDA approvals of the tumor ablation system
- 4.1.2. Restraints
  - 4.1.2.1. Challenges associated with the tumor ablation system
- 4.1.3. Opportunity
  - 4.1.3.1. Increasing collaborations and partnerships
- 4.1.4. Impact Analysis

5. Industry Analysis

5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID-19
- 6.1.2. Scenario During COVID-19
- 6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers' Strategic Initiatives
6.6. Conclusion

7. Russia-Ukraine War Analysis

8. By Technology

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 8.1.2. Market Attractiveness Index, By Technology
8.2. Radiofrequency (Rf) Ablation*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Microwave Ablation
8.4. Cryoablation
8.5. Other Technologies

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 9.1.2. Market Attractiveness Index, By Application
9.2. Liver Cancer*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Lung Cancer
9.4. Kidney Cancer
9.5. Bone Metastasis
9.6. Others

10. By Treatment Mode

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 10.1.2. Market Attractiveness Index, By Treatment Mode
10.2. Surgical Ablation*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Laparoscopic Ablation
10.4. Percutaneous Ablation

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.6.1. The U.S.
  - 11.2.6.2. Canada
  - 11.2.6.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.6.1. Germany
  - 11.3.6.2. The U.K.
  - 11.3.6.3. France
  - 11.3.6.4. Italy
  - 11.3.6.5. Spain
  - 11.3.6.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.6.1. Brazil
  - 11.4.6.2. Argentina
  - 11.4.6.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.6.1. China
  - 11.5.6.2. India
  - 11.5.6.3. Japan
  - 11.5.6.4. Australia
  - 11.5.6.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Mode

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Product Benchmarking
12.3. Company Share Analysis
12.4. Key Developments and Strategies

13. Company Profiles

13.1. Medtronic, PLC.*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. AngioDynamics Inc.
13.3. Boston Scientific Corporation
13.4. Healthtronics, Inc.
13.5. BVM Medical Limited
13.6. COMSOL Inc.
13.7. Galil Medical, Inc.
13.8. INTIO Inc.
13.9. Misonix, Inc.
13.10. NeuWave Medical, Inc.
13.11. SonaCare Medical, LLC